Standard Chartered stock rises as buyback rolls on; eyes on next results

Standard Chartered stock rises as buyback rolls on; eyes on next results

Standard Chartered shares rose 0.9% to 1,853 pence in early London trading Thursday, tracking gains in other UK banks. The bank disclosed buybacks of over 1 million shares on Jan. 12 and 13, with total buyback spending surpassing $1.15 billion. UK GDP grew 0.3% in November, beating forecasts and influencing rate cut expectations. Standard Chartered’s earnings report is due Feb. 24.
UOL stock rises after S$1.5 billion Hougang Central land win — what investors watch next

UOL stock rises after S$1.5 billion Hougang Central land win — what investors watch next

UOL shares rose about 2% Thursday after a consortium including the firm won a S$1.50 billion government tender for a major mixed-use site in Singapore. By 3:59 p.m. SGT, UOL traded at S$9.92 with volume near 2.25 million shares. The 46,899.4 sq m site will link to an MRT station and bus interchange. UOL holds a 30% stake in the residential portion; CapitaLand Development owns 50%.
ST Engineering stock rises as DBS lifts target price to S$10.20, flags “clearer winners” in defence, MRO

ST Engineering stock rises as DBS lifts target price to S$10.20, flags “clearer winners” in defence, MRO

ST Engineering shares rose 1.4% to S$9.52 by 3:37 p.m. Thursday after DBS raised its target price to S$10.20 and reiterated a “buy” rating. DBS cited stable earnings from defence and aviation services amid strong demand for maintenance work. Trading volume reached about 3.6 million shares. Investors await updates tied to the Singapore Airshow and the company’s full-year results in February.
15 January 2026

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. (Yahoo Finance) The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,”
Go toTop